Relief Therapeutics Discovers A Promising COVID-19 Killer

|
About: Relief Therapeutics Holding AG (RLFTF), Includes: GILD, INO, MRNA, NVAX, VIR
by: Croatoan Capital
This article is exclusive for subscribers.
Croatoan Capital
Long/Short Equity, event-driven, small-cap, Tech
Summary

Relief Therapeutics is in advanced clinical trials with their drug RLF-100 which aims to halt COVID-19 and reverse its devastating effects.

Just-released Compassionate Use results showed stunning results: ventilator-dependent COVID-19 patients with deadly comorbidities coming off the ventilator and returning home in only five days after treatment with RLF-100.

Relief Therapeutic's RLF-100 is both easy to manufacture at scale and inexpensive, meaning that success in clinical trials could translate to rapid worldwide production and availability.

If in-progress clinical trials reflect the Compassionate Use results, RLF-100 will likely garner immediate approval, and shares could go much higher.

Relief Therapeutics Holdings AG (OTCQB:RLFTF) is a Swiss Company that trades on the U.S. OTC Exchange in addition to its Swiss Stock Exchange Listing (RLF). Only a week ago, Relief Therapeutics was trading